BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Given Consensus Rating of "Moderate Buy" by Brokerages

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) have been given a consensus rating of "Moderate Buy" by the five research firms that are covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $15.60.

Several equities research analysts recently weighed in on the stock. Royal Bank of Canada reiterated an "outperform" rating and set a $10.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday, November 5th. Barclays increased their price target on BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the stock an "equal weight" rating in a research report on Tuesday, November 5th. Finally, Needham & Company LLC restated a "buy" rating and set a $14.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Tuesday, November 5th.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Deerfield Management Company L.P. Series C raised its stake in BioCryst Pharmaceuticals by 62.9% during the 2nd quarter. Deerfield Management Company L.P. Series C now owns 8,135,804 shares of the biotechnology company's stock valued at $50,279,000 after acquiring an additional 3,140,804 shares in the last quarter. Cubist Systematic Strategies LLC raised its stake in shares of BioCryst Pharmaceuticals by 528.0% during the second quarter. Cubist Systematic Strategies LLC now owns 1,112,232 shares of the biotechnology company's stock valued at $6,874,000 after purchasing an additional 935,132 shares in the last quarter. Fisher Asset Management LLC lifted its holdings in BioCryst Pharmaceuticals by 16.9% in the third quarter. Fisher Asset Management LLC now owns 3,338,062 shares of the biotechnology company's stock worth $25,369,000 after purchasing an additional 481,359 shares during the period. BNP Paribas Financial Markets grew its position in BioCryst Pharmaceuticals by 472.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 496,784 shares of the biotechnology company's stock valued at $3,776,000 after buying an additional 409,938 shares in the last quarter. Finally, Principal Financial Group Inc. increased its stake in BioCryst Pharmaceuticals by 1,058.1% during the 3rd quarter. Principal Financial Group Inc. now owns 411,414 shares of the biotechnology company's stock valued at $3,127,000 after buying an additional 375,890 shares during the period. 85.88% of the stock is owned by institutional investors.

BioCryst Pharmaceuticals Stock Performance

Shares of NASDAQ BCRX traded down $0.01 during trading on Friday, reaching $7.71. The stock had a trading volume of 998,002 shares, compared to its average volume of 2,823,892. The stock has a market cap of $1.60 billion, a PE ratio of -12.64 and a beta of 1.79. BioCryst Pharmaceuticals has a one year low of $4.03 and a one year high of $8.88. The firm's 50 day moving average price is $7.64 and its two-hundred day moving average price is $7.47.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last released its earnings results on Monday, November 4th. The biotechnology company reported ($0.07) earnings per share for the quarter, meeting the consensus estimate of ($0.07). The business had revenue of $117.10 million for the quarter, compared to the consensus estimate of $113.99 million. During the same quarter in the previous year, the firm earned ($0.19) EPS. The firm's revenue for the quarter was up 35.1% on a year-over-year basis. On average, research analysts expect that BioCryst Pharmaceuticals will post -0.38 earnings per share for the current year.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.